A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

NCT05686044 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

351

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Buntanetap/Posiphen
DRUG: Placebo

Sponsor

Annovis Bio Inc.